Data / Form D filings / Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc.: Form D filings
Avenzo Therapeutics, Inc., a biotechnology company in San Diego, CA, filed 4 Form D notices with the SEC between 2022 and 2025. The latest, on September 5, 2025, reports $47.2 million sold of a $75 million offering to 20 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 12707 High Bluff Drive, Suite 200, San Diego, CA, 92130
- Phone
- (858) 239-2944
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1947742
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | New notice | $75,000,000 | $47,230,787 | $27,769,213 | 20 | Aug 22, 2025 | sec.gov |
| Nov 20, 2024 | Amendment | $385,850,004 | $385,850,004 | 22 | Sep 14, 2022 | sec.gov | |
| Mar 26, 2024 | Amendment | $346,850,003 | $223,350,002 | $123,500,001 | 19 | Sep 14, 2022 | sec.gov |
| Sep 29, 2022 | New notice | $171,500,004 | $31,499,999 | $140,000,005 | 6 | Sep 14, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Carl Gordon | Director | |
| Garry Nicholson | Director | |
| Patrick Machado | Director | |
| Judith Li | Director | |
| Paolo Tombesi | Executive Officer | |
| Mohammad Hirmand | Executive Officer | |
| Simeon George | Director | |
| Scott Lipman | Executive Officer | |
| Athena Countouriotis | Executive Officer, Director | |
| Brian Sun | Executive Officer | |
| Jakob Dupont, M.D., M.A. | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Sep 1, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Avenzo Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.